Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Nausea|Vomiting
Interventions: DRUG: granisetron transdermal system|DRUG: fosaprepitant dimeglumine|OTHER: laboratory biomarker analysis
Sponsor: University of Southern California
Collaborators: National Cancer Institute (NCI)